Polymorphisms of DNA repair gene XRCC3 Thr241Met and risk of gastric cancer in a Chinese population

Mammalian cells are constantly exposed to a wide variety of genotoxic agents from both endogenous and exogenous sources. Genetic variability in DNA repair may contribute to human cancer risk. In this population-based case-control study in China, we tested the hypothesis that a C to T variant (Thr241Met) of DNA repair gene XRCC3 (X-ray repair cross-complementing group 3) is associated with risk of developing gastric cancer. We genotyped for this variant using polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP) in 188 histologically confirmed gastric cancer patients and 166 frequency-matched cancer-free controls. The XRCC3 genotype and allele frequencies were not significantly different between cases and controls (P = 0.99 for genotype; P = 0.76 for allele). The XRCC3 241Met allele frequency (4.8%) was significantly lower in healthy Chinese controls than previously reported healthy US Caucasian controls (38.9%). Compared with the XRCC3 241Thr/Thr genotype, the variant XRCC3241Thr/Met and Met/Met genotypes were not associated with an increased risk of gastric cancer (adjusted odds ratio (OR(a)), 1.06; 95% confidence interval (CI), 0.52-2.16). These findings suggest that polymorphisms of XRCC3 Thr241Met may not play a role in the etiology of gastric cancer. Further studies with a larger number of subjects and simultaneous measurement of different polymorphisms in DNA repair genes in the same pathway are needed to confirm these findings.     

Effects of salidroside on glioma formation and growth inhibition together with improvement of tumor microenvironment

Objective：To test the effects of salidroside on formation and growth of glioma together with tumor microenvironment.Methods：Salidroside extracted from Rhodiola rosea was purified and treated on human glioma cells U251 at the concentration of 20 μg/mL.3-（4,5-dimethylthiazol-2-yl）-2,5-dephenyltetrazolium bromide （MTT） assay for cytotoxicity and flow cytometry （FCM） for cell cycle analysis were performed.Then for in vivo study,xenotransplantation tumor model in nude mice was generated and treated with salidroside at the concentration of 50 mg/kg.d for totally 20 d.Body weight and tumor size were detected every 2 d after the treatment.The levels of 8-isoprostane,superoxide dismutase （SOD） and malondialdehyde （MDA）,special markers for oxidative stress,were detected while immunofluoresence staining was performed for astrocyte detection.Results：For in vitro study,salidroside could decrease the viability of human glioma cells U251 and the growth of U251 cells at G0/G1 checkpoint during the cell cycle.For in vivo study,salidroside could also inhibit the growth of human glioma tissue in nude mice.The body weight of these nude mice treated with salidroside did not decrease as quickly as control group.In the tumor xenotransplantation nude mice model,mice were found of inhibition of oxidative stress by detection of biomarkers.Furthermore,overgrowth of astrocytes due to the stimulation of oxidative stress in the cortex of brain was inhibited after the treatment of salidroside.Conclusions：Salidroside could inhibit the formation and growth of glioma both in vivo and in vitro and improve the tumor microenvironment via inhibition of oxidative stress and astrocytes.     

温针灸对功能性便秘患者临床症状及焦虑抑郁的改善作用

目的:探讨温针灸对功能性便秘(FC)患者临床症状及焦虑抑郁的改善作用。方法:选取2017年1月至2017年12月中国中医科学院广安门医院南区收治的FC患者70例作为研究对象,随机分为观察组和对照组,每组35例。对照组采用常规针刺治疗,观察组采用温针灸治疗,比较治疗前后2组患者便秘临床症状积分、首次排便时间、中医证候评分、焦虑自评量表(SAS)、抑郁自评量表(SDS)评分。结果:观察组有效率96. 00%,对照组有效率68. 00%,差异有统计学意义(P0. 05)。治疗后2组患者的周排便次数、粪便性状积分和排便困难程度均改善,中医证候评分、SAS和SDS评分下降,较治疗前差异有统计学意义(P 0. 05)。治疗后,观察组患者的周排便次数、粪便性状积分高于对照组,中医证候评分、SDS和SAS评分、首次排便时间以及排便困难程度积分小于对照组,差异有统计学意义(P 0. 05)。结论:温针灸治疗能调节胃肠道运动、润湿肠道、显著改善便秘等临床症状,对FC患者有显著临床效果。     

DF化疗、放疗序贯应用治疗食管癌疗效报道

 目的 食管癌化疗序贯放疗和单纯放疗疗效对比研究。方法 248 例食管癌随机分为综合治疗组125 例和单纯放疗组123 例。综合组：DDP（50mgm^{2>/sup> ,D1 ,8）5 FU（750mgm2>/sup> ,D2 6） 静脉注射,3 周为一周期,潘生丁50mg,口服,每天三次。2 3 周期化疗后放疗（DT60 70Gy6-5 7-5周）.单纯放疗组直接放疗（DT60 70Gy6-5 7-5 周）.结果 两组近期疗效无明显差别,综合组完全缓解率及1 ,3,5 年生存率高于单纯放疗组（p < 0-05）.结论 化疗后序贯放疗是治疗食管癌安全有效的方法。}     

Complete remission after autografting for chronic myeloid leukaemia

A previously untreated 31-yr old female with Ph-positive chronic myeloid leukaemia (CML) received busulphan and melphalan at high dosage followed by an autograft of peripheral blood stem cells collected 4 weeks earlier. Though recovering haemopoiesis was at first mainly Ph-positive, Ph-negative haemopoiesis predominated at 12 months and has persisted until the most recent study (24 months post-autograft). Her haemopoietic cells now show no rearrangement of the bcr gene, unlike the cells collected at diagnosis. Autografting carried out soon after diagnosis could be valuable for obtaining cytogenetic remissions in other patients with CML.     

人卵巢癌裸鼠移植腹水瘤模型的建立

建立人卵巢癌裸鼠移植腹水瘤模型,为研究人卵巢癌发病机制,生物学特性以及转移方式提供工具。方法将１例人卵巢癌的腹水直接接种于裸鼠腹腔,观察裸鼠腹水形以及肿瘤生长和转移情况,做腹水细胞学计数、涂片以及染色体和肿瘤标志物的检查,肿瘤和器官作病理学检查。结果成功建成１个人卵巢癌裸鼠移植腹水瘤模型,并已传至第１８代,传代移植成功率１００．０％,组织学和超微结构结构形态证实,保持了原人卵巢癌特征,具有人类肿瘤     

替吉奥或卡培他滨联合奥沙利铂治疗晚期胃癌效果比较

目的：对比替吉奥联合奥沙利铂（L-OHP）与卡培他滨联合L-OHP治疗晚期胃癌的疗效和不良反应。方法对2011年3月至2014年12月郑州人民医院收治的93例晚期胃癌患者资料进行回顾性分析。其中替吉奥联合L-OHP治疗组（SL组）48例,卡培他滨联合L-OHP治疗组（XL组）45例。SL组：给予替吉奥每天80 mg／m2,分两次口服,第1天至第14天;L-OHP 130 mg／m2,静脉滴注2 h,第1天。XL组：卡培他滨每天2000 mg／m2,分两次口服,第1天至第14天;L-OHP 130 mg／m2,静脉滴注2 h,第1天。化疗周期为21 d。完成2个周期后评估疗效和不良反应。结果SL组和XL组总有效率分别为52.08%（25／48）和53.33%（24／45）,差异无统计学意义（P＞0.05）。SL组消化道不良反应发生率高于XL组[52.08%（25／48）和24.44%（11／45）,P＜0.05]。SL组口腔黏膜炎发生率低于XL组[25.00%（12／48）和51.11%（23／45）,P <0.05]。结论替吉奥联合L-OHP与卡培他滨联合L-OHP治疗晚期胃癌均安全、有效。     

伊达比星加中剂量阿糖胞苷强化疗对急性髓系白血病预后的影响

目的：观察伊达比星加中剂量阿糖胞苷强化疗治疗急性髓系白血病（AML）的疗效和安全性。方法以北京军区总医院血液科2010年1月至2015年1月应用中剂量阿糖胞苷（2 g／m2,1次／12 h,第1天至第3天）联合伊达比星（12 mg／m2第1天）强化巩固治疗的50例诱导化疗缓解的 AML 患者为试验组,选择同期单药阿糖胞苷（2 g／m2,1次／12 h,第1天至第3天）治疗的50例患者为对照组。两组患者均序贯治疗6个疗程,试验组男性28例,女性22例,平均年龄27.6岁（18～52岁）,原发病包括M1型3例,M2型27例,M4型8例,M5型12例;对照组男性30例,女性20例,平均年龄26.8岁（16～50岁）,原发病包括 M1型2例,M2型30例,M4型8例,M5型10例。观察两组患者化疗并发症和无病生存等情况。结果随访至2015年6月,试验组1例死于肺部感染,2例死于感染性休克;对照组3例死于肺部感染,1例死于感染性休克。试验组和对照组患者治疗相关死亡率分别为6%（3／50）、8%（4／50）（P＞0.05）,复发率分别为32%（16／50）、52%（26／50）（P＜0.05）,无病生存率分别为62%（31／50）、40%（20／50）（P＜0.05）。结论伊达比星加中剂量阿糖胞苷强化疗治疗 AML 与单药阿糖胞苷相比复发率降低,无病生存率显著提高,且治疗相关死亡未增加,值得临床进一步应用。     

HSV1—TK转染人肺腺癌细胞A549的实验研究

目的体内外观察HSV     

微波固化保肢术后成骨肉瘤患者红细胞免疫功能的变化

研究微波固化保肢术提高患者生存率的免疫学机制。方法应用色散比浊法检测患者血清Ｃ３、Ｃ４含量,应用红细胞Ｃ３ｂ受体花环、免疫复合物花环及直接肿瘤花环检测红细胞免疫功能。